Health
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS
About this update from Johnson & Johnson
[{"type":"text","content":"TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need populationMajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new standard of care as early as first relapse","length":240,"tagName":"p"},{"type":"text","content":"RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS) with TECVAYLI® compared to standard of care as early as second line.1","length":630,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YyQxtwHN0OWd0z9HyFy.lg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b","width":400,"height":37}},"href":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Multiple myeloma is a blood cancer characterized by high rates of relapse. Despite recent advances in treatment, a significant unmet need remains for additional, well–tolerated therapies—particularly in earlier lines of therapy for patients refractory to anti–CD38 monoclonal antibodies and lenalidomide, commonly used medications in multiple myeloma.","length":351,"tagName":"p"},{"type":"text","content":"The MajesTEC-9 study evaluated TECVAYLI® monotherapy in patients predominantly refractory to anti-CD38 and lenalidomide therapies.1 These results build on the unprecedented MajesTEC-3 findings published in The New England Journal of Medicine, which showed significant PFS and OS benefits with TECVAYLI® plus DARZALEX FASP...